Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Multiple Sclerosis

  Free Subscription


1 Brain
1 J Clin Invest
1 J Neurol
2 J Neurol Sci
7 Mult Scler
5 Neurology
1 Rev Neurol (Paris)

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles


  1. RODGERS J, Friede T, Vonberg FW, Constantinescu CS, et al
    The impact of smoking cessation on multiple sclerosis disease progression.
    Brain. 2021 Oct 8. pii: 6384574. doi: 10.1093.
    PubMed         Abstract available

    J Clin Invest

  2. SINGH AK, Netea MG, Bishai WR
    BCG turns 100: its nontraditional uses against viruses, cancer, and immunologic diseases.
    J Clin Invest. 2021;131.
    PubMed         Abstract available

    J Neurol

  3. PREZIOSA P, Conti L, Rocca MA, Filippi M, et al
    Effects on cognition of DMTs in multiple sclerosis: moving beyond the prevention of inflammatory activity.
    J Neurol. 2021 Oct 7. pii: 10.1007/s00415-021-10832.
    PubMed         Abstract available

    J Neurol Sci

  4. PLOWMAN RS, Varma H
    Prognostic factors in Tumefactive demyelinating lesions: A retrospective study.
    J Neurol Sci. 2021;428:117591.
    PubMed         Abstract available

  5. XIE JS, Jeeva-Patel T, Margolin E
    Balo's concentric sclerosis - A rare entity within the spectrum of demyelinating diseases.
    J Neurol Sci. 2021;428:117570.
    PubMed         Abstract available

    Mult Scler

  6. WEINSTOCK Z, Morrow S, Conway D, Fuchs T, et al
    Interpreting change on the Symbol Digit Modalities Test in people with relapsing multiple sclerosis using the reliable change methodology.
    Mult Scler. 2021 Oct 6:13524585211049397. doi: 10.1177/13524585211049397.
    PubMed         Abstract available

  7. BAR-OR A, Wiendl H, Montalban X, Alvarez E, et al
    Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study.
    Mult Scler. 2021 Oct 4:13524585211044479. doi: 10.1177/13524585211044479.
    PubMed         Abstract available

  8. BOSMA AR, Murley C, Aspling J, Hillert J, et al
    Trajectories of sickness absence and disability pension days among people with multiple sclerosis by type of occupation.
    Mult Scler. 2021 Oct 6:13524585211048759. doi: 10.1177/13524585211048759.
    PubMed         Abstract available

  9. SOLOMON AJ, Kaisey M, Krieger SC, Chahin S, et al
    Multiple sclerosis diagnosis: Knowledge gaps and opportunities for educational intervention in neurologists in the United States.
    Mult Scler. 2021 Oct 6:13524585211048401. doi: 10.1177/13524585211048401.
    PubMed         Abstract available

    Personalized medicine for multiple sclerosis: How to integrate neurofilament light chain levels in the decision?
    Mult Scler. 2021 Oct 6:13524585211049552. doi: 10.1177/13524585211049552.

  11. UHER T, Havrdova EK, Benkert P, Bergsland N, et al
    Measurement of neurofilaments improves stratification of future disease activity in early multiple sclerosis.
    Mult Scler. 2021 Oct 6:13524585211047977. doi: 10.1177/13524585211047977.
    PubMed         Abstract available

  12. ZHONG M, van der Walt A, Stankovich J, Kalincik T, et al
    Prediction of multiple sclerosis outcomes when switching to ocrelizumab.
    Mult Scler. 2021 Oct 8:13524585211049986. doi: 10.1177/13524585211049986.
    PubMed         Abstract available


  13. HACOHEN Y, Eshaghi A
    Multiple Sclerosis in Children and Adults: Does Age Matter?
    Neurology. 2021 Oct 4. pii: WNL.0000000000012866.

  14. BONACCHI R, Meani A, Pagani E, Marchesi O, et al
    Association of Age at Onset With Gray Matter Volume and White Matter Microstructural Abnormalities in People With Multiple Sclerosis.
    Neurology. 2021 Oct 4. pii: WNL.0000000000012869.
    PubMed         Abstract available

  15. KILLESTEIN J, Schoonheim MM, Voskuhl RR
    B-Cell Depletion and COVID-19 Severity in Multiple Sclerosis: Remaining Challenges.
    Neurology. 2021 Oct 5. pii: WNL.0000000000012754.

  16. SIMPSON-YAP S, De Brouwer E, Kalincik T, Rijke N, et al
    Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis.
    Neurology. 2021 Oct 5. pii: WNL.0000000000012753.
    PubMed         Abstract available

  17. SECHI E, Krecke KN, Messina SA, Buciuc M, et al
    Comparison of MRI Lesion Evolution in Different Central Nervous System Demyelinating Disorders.
    Neurology. 2021 Jul 14. pii: WNL.0000000000012467.
    PubMed         Abstract available

    Rev Neurol (Paris)

  18. MICHEL M, Le Page E, Laplaud DA, Wardi R, et al
    Cost-utility of oral methylprednisolone in the treatment of multiple sclerosis relapses: Results from the COPOUSEP trial.
    Rev Neurol (Paris). 2021 Sep 28. pii: S0035-3787(21)00664.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.